Needles—Essential For Sewing, But Maybe Not For People With Certain Inflammatory Conditions
XELJANZ is a pill approved to treat adults when TNF blockers did not work well or could not be tolerated with:
XELJANZ is approved to treat patients ages 2 and older when TNF blockers did not work well or could not be tolerated with:
patients in focus
A Closer Look at Real Patient Stories
Learn more about real adult XELJANZ patients with moderate to severe rheumatoid arthritis (RA), active psoriatic arthritis (PsA), and moderate to severe ulcerative colitis (UC). They were prescribed XELJANZ after TNF blockers did not work well or could not be tolerated. As ambassadors, they share their treatment stories to remind you that you’re not alone. Individual results may vary. Patient ambassador stories have been developed in partnership with Pfizer.
10 Years in RA
XELJANZ has been prescribed for more than 10 years, since initial approval in 2012, for adults with moderate to severe rheumatoid arthritis.* XELJANZ was approved for use in adults with active psoriatic arthritis* in 2017, adults with moderate to severe ulcerative colitis* in 2018, and adults with active ankylosing spondylitis in 2021.
In 2020, XELJANZ was approved for use in patients ages 2 and older with active polyarticular course juvenile idiopathic arthritis.*
*Indication revised to use in patients who have not responded or cannot tolerate one or more TNF blockers.
Getting Started With XELJANZ
How XELJANZ Works
XELJANZ is a Janus kinase (JAK) inhibitor that helps regulate an overactive immune system. It helps disrupt JAK pathways from inside the cells, which are believed to play a role in inflammation.
Discover Support Resources
Take an active role in your treatment with tools and support resources—delivered directly to you. We’ll start by sending a Welcome Kit in the mail and will follow up with occasional emails containing timely information and lifestyle tips.